Birchview Capital’s enGene Therapeutics ENGN Stock Holding History

Birchview Capital’s Portfolio ENGN Stock Details ENGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-250,000	Closed	-$1.7M	–	75
2026 Q1	$1.7M	Buy	+250,000	New	+$2.23M	0.97%	31

Other funds holding ENGN

FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Birchview Capital's ENGN Position: Q2 2026 in Review

Birchview Capital sold out of enGene Therapeutics (ENGN) in Q2 2026, closing a stake of 250,000 shares — an estimated $1.7M sold.

Birchview Capital first reported a position in ENGN in Q1 2026 and held it in 1 quarter. The position peaked at $1.7M in Q1 2026. 60 funds tracked by Wall St. Rank hold ENGN as of Q2 2026.

Birchview Capital reported no remaining enGene Therapeutics position as of Q2 2026 after selling out during the quarter.
Birchview Capital sold 250,000 enGene Therapeutics shares in Q2 2026, an estimated $1.7M.
Birchview Capital first reported a position in enGene Therapeutics in Q1 2026 and held it in 1 quarter.
Birchview Capital's enGene Therapeutics position peaked at $1.7M in Q1 2026.
60 funds tracked by Wall St. Rank held enGene Therapeutics as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.